FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

The proposal would exclude some medicines from mass compounding unless they are on the FDA's drug shortage list. That would likely constrain supply and reduce flexibility for affected drugmakers and compounding pharmacies. The article is narrowly regulatory in nature, with limited immediate market impact unless finalized and expanded.

Analysis

The proposal would exclude some medicines from mass compounding unless they are on the FDA's drug shortage list. That would likely constrain supply and reduce flexibility for affected drugmakers and compounding pharmacies. The article is narrowly regulatory in nature, with limited immediate market impact unless finalized and expanded.